Clinical trial
A Phase II Trial of Oxaliplatin and Capecitabine in the Treatment of Patients With Relapsed/Refractory Carcinoma of Unknown Primary Site
NCT00193609 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Oxaliplatin and Capecitabine in the Treatment of Patients With Relapsed/Refractory Carcinoma of Unknown Primary Site
- Lead sponsor
- SCRI Development Innovations, LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2004
- Completion date
- January 31, 2009
- Enrollment
- 48 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.